All Stories

  1. An evaluation of tedizolid for the treatment of MRSA infections

    Article • Expert Opinion on Pharmacotherapy, September 2018, Taylor & Francis

    Ronald Hall

  2. Impact of total body weight on 30-day mortality in patients with gram-negative bacteremia

    Article • Expert Review of Anti-infective Therapy, May 2017, Taylor & Francis

    Ronald Hall, Andrew Faust, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  3. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)

    Article • Expert Review of Clinical Pharmacology, March 2017, Taylor & Francis

    Ronald Hall

  4. Low-Molecular-Weight Heparin Prophylaxis Dosing

    Article • Journal of Pharmacy Technology, November 2015, SAGE Publications

    Ronald Hall

  5. Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World

    Article • Current Pharmaceutical Design, October 2015, Bentham Science Publishers

    Ronald Hall

  6. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections

    Article • Infection and Drug Resistance, April 2015, Taylor & Francis

    Ronald Hall

  7. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

    Article • BMC Infectious Diseases, March 2014, Springer Science + Business Media

    Ronald Hall

  8. Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents

    Article • Annals of Pharmacotherapy, November 2013, SAGE Publications

    Ronald Hall

  9. Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

    Article • Antimicrobial Agents and Chemotherapy, March 2013, ASM Journals

    Ronald Hall

  10. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

    Article • BMC Pharmacology and Toxicology, February 2013, Springer Science + Business Media

    Ronald Hall, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  11. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

    Article • BMC Infectious Diseases, April 2012, Springer Science + Business Media

    Ronald Hall, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  12. Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People

    Article • Antimicrobial Agents and Chemotherapy, August 2011, ASM Journals

    Ronald Hall

  13. Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind

    Article • Journal of Intensive Care Medicine, July 2010, SAGE Publications

    Ronald Hall

  14. Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?

    Article • The American Journal of Medicine, February 2010, Elsevier

    Ronald Hall

  15. Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2009, Wiley

    Ronald Hall

  16. Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

    Article • Journal of Cardiovascular Pharmacology, June 2008, Wolters Kluwer Health

    Ronald Hall

  17. Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity

    Article • The American Journal of Medicine, June 2008, Elsevier

    Ronald Hall